Current unmet needs in renal transplantation: A review of challenges and therapeutics

Frontiers in Bioscience - Elite

Volumn 8, Issue 1, 2016, Pages 1-14

  Walsh, Liron ^a   Dinavahi, Rajani ^a  

^a AMGEN INC   (United States)

Author keywords

Antibody mediated rejection; Chronic allograft nephropathy; Delayed graft function; Post transplant malignancy; Review; Transplant glomerulopathy; Transplantation

Indexed keywords

ANTIBODY MEDIATED REJECTION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL (TOPIC); DELAYED GRAFT FUNCTION; GLOMERULOPATHY; HUMAN; KIDNEY TRANSPLANTATION; NONHUMAN; REVIEW; GLOMERULUS; GRAFT REJECTION; HEALTH SERVICE; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

GRAFT REJECTION; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; NEOPLASMS;

EID: 84991388002     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e746     Document Type: Review

References (101)

1. Meier-Kriesche, H U, J D Schold and B Kaplan: Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant, 4(8), 1289-95 (2004) DOI: 10.1111/j.1600-6143.2004.00515.x
2. J. Snyder, A M, S. Leppke, A. Israni, B. Kasiske: Causes of Kidney Allograft Loss and Death in the United States, 2000-2010. In: American Transplant Congress. Seattle, Wa (2013)
3. Siedlecki, A, W Irish and D C Brennan: Delayed graft function in the kidney transplant. Am J Transplant, 11(11), 2279-96 (2011) DOI: 10.1111/j.1600-6143.2011.03754.x
4. Phelan, P J, P O'Kelly, M Tarazi, N Tarazi, M R Salehmohamed, D M Little, C Magee and P J Conlon: Renal allograft loss in the first post-operative month: causes and consequences. Clin Transplant, 26(4), 544-9 (2012) DOI: 10.1111/j.1399-0012.2011.01581.x
5. Legendre, C, G Canaud and F Martinez: Factors influencing long-term outcome after kidney transplantation. Transpl Int, 27(1), 19-27 (2014) DOI: 10.1111/tri.12217
6. Ponticelli, C, M Villa, B Cesana, G Montagnino and A Tarantino: Risk factors for late kidney allograft failure. Kidney Int, 62(5), 1848-54 (2002)
7. Michael, H J, G C Francos, J F Burke, A Besarab, M Moritz, D Gillum and B Jarrell: A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation, 48(5), 805-8 (1989) DOI: 10.1097/00007890-198911000-00016
8. Goggins, W C, M A Pascual, J A Powelson, C Magee, N Tolkoff-Rubin, M L Farrell, D S Ko, W W Williams, A Chandraker, F L Delmonico, H Auchincloss and A B Cosimi: A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation, 76(5), 798-802 (2003) DOI: 10.1097/01.TP.0000081042.67285.91
9. Agarwal, A, P Murdock and J A Fridell: Comparison of histidine-tryptophan ketoglutarate solution and University of Wisconsin solution in prolonged cold preservation of kidney allografts. Transplantation, 81(3), 480-2 (2006) DOI: 10.1097/01.tp.0000196724.89757.79
10. Lynch, R J, J Kubus, R H Chenault, S J Pelletier, D A Campbell and M J Englesbe: Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin preservation in renal transplantation. Am J Transplant, 8(3), 567-73 (2008) DOI: 10.1111/j.1600-6143.2007.02065.x
11. Klaus, F, D B Castro, C M Bittar, A E Bittar, E Keitel, D C Seelig, J C Goldani, M H Meinne and V D Garcia: Kidney transplantation with Belzer or Custodiol solution: a randomized prospective study. Transplant Proc, 39(2), 353-4 (2007) DOI: 10.1016/j.transproceed.2007.01.009
12. Cavaille-Coll, M, S Bala, E Velidedeoglu, A Hernandez, P Archdeacon, G Gonzalez, C Neuland, J Meyer and R Albrecht: Summary of FDA workshop on ischemia reperfusion injury in kidney transplantation. Am J Transplant, 13(5), 1134-48 (2013) DOI: 10.1111/ajt.12210
13. Wever, K E, F A Wagener, C Frielink, O C Boerman, G J Scheffer, A Allison, R Masereeuw and G A Rongen: Diannexin protects against renal ischemia reperfusion injury and targets phosphatidylserines in ischemic tissue. PLoS ONE [Electronic Resource], 6(8), e24276 (2011) DOI: 10.1371/journal.pone.0024276
14. Neidlinger, N A, E R Hirvela, R A Skinner, S K Larkin, A H Harken and F A Kuypers: Postinjury serum secretory phospholipase A2 correlates with hypoxemia and clinical status at 72 hours. Journal of the American College of Surgeons, 200(2), 173-8 (2005) DOI: 10.1016/j.jamcollsurg.2004.10.010
15. Cooper M, K S, Stratta R: Diannexin, a novel ischemia/reperfusion therapeutic agent, reduces delayed graft function (DGF) in renal transplant recipients from marginal donors. Am J Transplant, 10(suppl 4):83. Abstract 145 (2010)
16. Fujino, T, S Muhib, N Sato and N Hasebe: Silencing of p53 RNA through transarterial delivery ameliorates renal tubular injury and downregulates GSK-3beta expression after ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 305(11), F1617-27 (2013) DOI: 10.1152/ajprenal.00279.2013
17. Record Owner, N L M: P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor
18. Molitoris, B A, P C Dagher, R M Sandoval, S B Campos, H Ashush, E Fridman, A Brafman, A Faerman, S J Atkinson, J D Thompson, H Kalinski, R Skaliter, S Erlich and E Feinstein: siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. Journal of the American Society of Nephrology, 20(8), 1754-64 (2009) DOI: 10.1681/ASN.2008111204
19. Arslan, F, B Keogh, P McGuirk and A E Parker: TLR2 and TLR4 in ischemia reperfusion injury. Mediators of Inflammation, 2010, 704202 (2010)
20. Record Owner, N L M: Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury.
21. de Vries, D K, P van der Pol, G E van Anken, D J van Gijlswijk, J Damman, J H Lindeman, M E Reinders, A F Schaapherder and C Kooten: Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation, 95(6), 816-20 (2013) DOI: 10.1097/TP.0b013e31827e31c9
22. Kelly, R J, A Hill, L M Arnold, G L Brooksbank, S J Richards, M Cullen, L D Mitchell, D R Cohen, W M Gregory and P Hillmen: Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood, 117(25), 6786-92 (2011) DOI: 10.1182/blood-2011-02-333997
23. Tanimoto, T, Y Oshima and M Kami: Eculizumab in atypical hemolytic-uremic syndrome. New England Journal of Medicine, 369(14), 1378-9 (2013)
24. Zuber, J, M Le Quintrec, S Krid, C Bertoye, V Gueutin, A Lahoche, N Heyne, G Ardissino, V Chatelet, L H Noel, M Hourmant, P Niaudet, V Fremeaux-Bacchi, E Rondeau, C Legendre, C Loirat and H U S French Study Group for Atypical: Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. American Journal of Transplantation, 12(12), 3337-54 (2012) DOI: 10.1111/j.1600-6143.2012.04252.x
25. Kocak, B, E Arpali, E Demiralp, B Yelken, C Karatas, S Gorcin, N Gorgulu, M Uzunalan, A Turkmen and M Kalayoglu: Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplantation Proceedings, 45(3), 1022-5 (2013) DOI: 10.1016/j.transproceed.2013.02.062
26. Lewis, A G, G Kohl, Q Ma, P Devarajan and J Kohl: Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. Clin Exp Immunol, 153(1), 117-26 (2008) DOI: 10.1111/j.1365-2249.2008.03678.x
27. Gaber, A O, S Mulgaonkar, B D Kahan, E S Woodle, R Alloway, I Bajjoka, S Jensik, G B Klintmalm, P R Patton, A Wiseman, G Lipshutz, J Kupiec-Weglinski, L W Gaber, E Katz, W Irish, E C Squiers and S Hemmerich: YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study. Clin Transplant, 25(4), 523-33 (2011) DOI: 10.1111/j.1399-0012.2010.01295.x
28. Salmela, K, L Wramner, H Ekberg, I Hauser, O Bentdal, L E Lins, H Isoniemi, L Backman, N Persson, H H Neumayer, P F Jorgensen, C Spieker, B Hendry, A Nicholls, G Kirste and G Hasche: A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation, 67(5), 729-36 (1999) DOI: 10.1097/00007890-199903150-00015
29. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States In, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (2013)
30. Farrugia, D, S Mahboob, J Cheshire, I Begaj, S Khosla, D Ray and A Sharif: Malignancy-related mortality following kidney transplantation is common. Kidney Int (2013)
31. Kasiske, B L, J J Snyder, D T Gilbertson and C Wang: Cancer after kidney transplantation in the United States. Am J Transplant, 4(6), 905-13 (2004) DOI: 10.1111/j.1600-6143.2004.00450.x
32. Sampaio, M S, Y W Cho, Y Qazi, S Bunnapradist, I V Hutchinson and T Shah: Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database. Transplantation, 94(10), 990-8 (2012) DOI: 10.1097/TP.0b013e318270bc7b
33. Wimmer, C D, M Rentsch, A Crispin, W D Illner, H Arbogast, C Graeb, K W Jauch and M Guba: The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int, 71(12), 1271-8 (2007) DOI: 10.1038/sj.ki.5002154
34. Grulich, A E, M T van Leeuwen, M O Falster and C M Vajdic: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet, 370(9581), 59-67 (2007) DOI: 10.1016/S0140-6736(07)61050-2
35. Gutierrez-Dalmau, A and J M Campistol: Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs, 67(8), 1167-98 (2007) DOI: 10.2165/00003495-200767080-00006
36. Guba, M, C Graeb, K W Jauch and E K Geissler: Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation, 77(12), 1777-82 (2004) DOI: 10.1097/01.TP.0000120181.89206.54
37. Kauffman, H M, W S Cherikh, Y Cheng, D W Hanto and B D Kahan: Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation, 80(7), 883-9 (2005) DOI: 10.1097/01.TP.0000184006.43152.8D
38. Schena, F P, M D Pascoe, J Alberu, M del Carmen Rial, R Oberbauer, D C Brennan, J M Campistol, L Racusen, M S Polinsky, R Goldberg-Alberts, H Li, J Scarola, J F Neylan and C T S G Sirolimus: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation, 87(2), 233-42 (2009) DOI: 10.1097/TP.0b013e3181927a41
39. Luan, F L, M Hojo, M Maluccio, K Yamaji and M Suthanthiran: Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation, 73(10), 1565-72 (2002) DOI: 10.1097/00007890-200205270-00008
40. Glotz, D, B Charpentier, D Abramovicz, P Lang, L Rostaing, G Rifle, Y Vanrenterghem, F Berthoux, B Bourbigot, M Delahousse, J M Chalopin, E Cassuto and N Lefrancois: Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation, 89(12), 1511-7 (2010) DOI: 10.1097/TP.0b013e3181db09e4
41. Kaplan, B, Y Qazi and J R Wellen: Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) (2014)
42. Tressler, R J, L J Garvin and D L Slate: Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer, 57(4), 568-73 (1994) DOI: 10.1002/ijc.2910570421
43. Opelz, G and B Dohler: Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant, 4(2), 222-30 (2004) DOI: 10.1046/j.1600-6143.2003.00325.x
44. Bakker, N A and G W van Imhoff: Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention? Haematologica, 92(11), 1447-50 (2007) DOI: 10.3324/haematol.11272
45. Brennan, D C and M A Schnitzler: Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med, 359(16), 1736-8 (2008) DOI: 10.1056/NEJMc0805714
46. Brokhof, M M, H W Sollinger, D R Hager, B L Muth, J D Pirsch, L A Fernandez, J M Bellingham, J D Mezrich, D P Foley, A M D'Alessandro, J S Odorico, M A Mohamed, V Vidyasagar, T M Ellis, D B Kaufman and A Djamali: Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation, 97(6), 612-7 (2014) DOI: 10.1097/TP.0000000000000031
47. Hariharan, S, C P Johnson, B A Bresnahan, S E Taranto, M J McIntosh and D Stablein: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med, 342(9), 605-12 (2000) DOI: 10.1056/NEJM200003023420901
48. Montgomery, R A, M A Hardy, S C Jordan, L C Racusen, L E Ratner, D B Tyan, A A Zachary, r Antibody Working Group on the diagnosis, r risk assessment for antibody-mediated and p desensitization: Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation, 78(2), 181-5 (2004) DOI: 10.1097/01.TP.0000129256.84027.D6
49. Nair, N, T Ball, P A Uber and M R Mehra: Current and future challenges in therapy for antibody-mediated rejection. J Heart Lung Transplant, 30(6), 612-7 (2011) DOI: 10.1016/j.healun.2011.02.002
50. Amico, P, G Honger, M Mayr, J Steiger, H Hopfer and S Schaub: Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation, 87(11), 1681-8 (2009) DOI: 10.1097/TP.0b013e3181a5e034
51. Gloor, J M, J L Winters, L D Cornell, L A Fix, S R De Goey, R M Knauer, F G Cosio, M J Gandhi, W Kremers and M D Stegall: Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant, 10(3), 582-9 (2010) DOI: 10.1111/j.1600-6143.2009.02985.x
52. Patel, R and P I Terasaki: Significance of the positive crossmatch test in kidney transplantation. N Engl J Med, 280(14), 735-9 (1969) DOI: 10.1056/NEJM196904032801401
53. Akalin, E and B Watschinger: Antibody-mediated rejection. Semin Nephrol, 27(4), 393-407 (2007) DOI: 10.1016/j.semnephrol.2007.05.001
54. Issa, N, F G Cosio, J M Gloor, S Sethi, P G Dean, S B Moore, S De Goey and M D Stegall: Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation, 86(5), 681-5 (2008) DOI: 10.1097/TP.0b013e3181837626
55. Gloor, J M, S R De Goey, A A Pineda, S B Moore, M Prieto, S L Nyberg, T S Larson, M D Griffin, S C Textor, J A Velosa, T R Schwab, L A Fix and M D Stegall: Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant, 3(8), 1017-23 (2003) DOI: 10.1034/j.1600-6143.2003.00180.x
56. Montgomery, R A, A A Zachary, L C Racusen, M S Leffell, K E King, J Burdick, W R Maley and L E Ratner: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation, 70(6), 887-95 (2000) DOI: 10.1097/00007890-200009270-00006
57. Schweitzer, E J, J S Wilson, M Fernandez-Vina, M Fox, M Gutierrez, A Wiland, J Hunter, A Farney, B Philosophe, J Colonna, B E Jarrell and S T Bartlett: A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation, 70(10), 1531-6 (2000) DOI: 10.1097/00007890-200011270-00023
58. Montgomery, R A, J E Locke, K E King, D L Segev, D S Warren, E S Kraus, M Cooper, C E Simpkins, A L Singer, Z A Stewart, J K Melancon, L Ratner, A A Zachary and M Haas: ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation, 87(8), 1246-55 (2009) DOI: 10.1097/TP.0b013e31819f2024
59. Jordan, S C, D Tyan, L Czer and M Toyoda: Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Pediatr Transplant, 2(2), 92-105 (1998)
60. Yu, Z and V A Lennon: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med, 340(3), 227-8 (1999) DOI: 10.1056/NEJM199901213400311
61. Everly, M J, J J Everly, B Susskind, P Brailey, L J Arend, R R Alloway, P Roy-Chaudhury, A Govil, G Mogilishetty, A H Rike, M Cardi, G Wadih, A Tevar and E S Woodle: Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation, 86(12), 1754-61 (2008) DOI: 10.1097/TP.0b013e318190af83
62. Walsh, R C, J J Everly, P Brailey, A H Rike, L J Arend, G Mogilishetty, A Govil, P Roy-Chaudhury, R R Alloway and E S Woodle: Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation, 89(3), 277-84 (2010) DOI: 10.1097/TP.0b013e3181c6ff8d
63. Stegall, M D, T Diwan, S Raghavaiah, L D Cornell, J Burns, P G Dean, F G Cosio, M J Gandhi, W Kremers and J M Gloor: Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant, 11(11), 2405-13 (2011) DOI: 10.1111/j.1600-6143.2011.03757.x
64. Bray, R A and H M Gebel: Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant, 14(4), 392-7 (2009) DOI: 10.1097/MOT.0b013e32832d31c7
65. Archdeacon, P, M Chan, C Neuland, E Velidedeoglu, J Meyer, L Tracy, M Cavaille-Coll, S Bala, A Hernandez and R Albrecht: Summary of FDA antibody-mediated rejection workshop. Am J Transplant, 11(5), 896-906 (2011) DOI: 10.1111/j.1600-6143.2011.03525.x
66. Meier-Kriesche, H U, J D Schold, T R Srinivas and B Kaplan: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant, 4(3), 378-83 (2004) DOI: 10.1111/j.1600-6143.2004.00332.x
67. Nankivell, B J, R J Borrows, C L Fung, P J O'Connell, R D Allen and J R Chapman: The natural history of chronic allograft nephropathy. N Engl J Med, 349(24), 2326-33 (2003) DOI: 10.1056/NEJMoa020009
68. Paul, L C: Chronic allograft nephropathy: An update. Kidney Int, 56(3), 783-93 (1999) DOI: 10.1046/j.1523-1755.1999.00611.x
69. Paul, L C: Chronic renal transplant loss. Kidney Int, 47(6), 1491-9 (1995) DOI: 10.1038/ki.1995.211
70. Solez, K, R B Colvin, L C Racusen, B Sis, P F Halloran, P E Birk, P M Campbell, M Cascalho, A B Collins, A J Demetris, C B Drachenberg, I W Gibson, P C Grimm, M Haas, E Lerut, H Liapis, R B Mannon, P B Marcus, M Mengel, M J Mihatsch, B J Nankivell, V Nickeleit, J C Papadimitriou, J L Platt, P Randhawa, I Roberts, L Salinas-Madriga, D R Salomon, D Seron, M Sheaff and J J Weening: Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant, 7(3), 518-26 (2007) DOI: 10.1111/j.1600-6143.2006.01688.x
71. Nankivell, B J and J R Chapman: Chronic allograft nephropathy: current concepts and future directions. Transplantation, 81(5), 643-54 (2006) DOI: 10.1097/01.tp.0000190423.82154.01
72. Almond, P S, A Matas, K Gillingham, D L Dunn, W D Payne, P Gores, R Gruessner and J S Najarian: Risk factors for chronic rejection in renal allograft recipients. Transplantation, 55(4), 752-6; discussion 756-7 (1993) DOI: 10.1097/00007890-199304000-00013
73. Massy, Z A, C Guijarro, M R Wiederkehr, J Z Ma and B L Kasiske: Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int, 49(2), 518-24 (1996) DOI: 10.1038/ki.1996.74
74. Kasiske, B L, R S Kalil, H S Lee and K V Rao: Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int, 40(3), 514-24 (1991) DOI: 10.1038/ki.1991.240
75. Matas, A J, K J Gillingham, W D Payne and J S Najarian: The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation, 57(6), 857-9 (1994) DOI: 10.1097/00007890-199403270-00015
76. Chapman, J R: Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations. Kidney Int Suppl(99), S108-12 (2005) DOI: 10.1111/j.1523-1755.2005.09920.x
77. Nankivell, B J, R J Borrows, C L Fung, P J O'Connell, J R Chapman and R D Allen: Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation, 78(4), 557-65 (2004) DOI: 10.1097/01.TP.0000128636.70499.6E
78. Solez, K, F Vincenti and R S Filo: Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation, 66(12), 1736-40 (1998) DOI: 10.1097/00007890-199812270-00029
79. Racusen, L C, K Solez, R B Colvin, S M Bonsib, M C Castro, T Cavallo, B P Croker, A J Demetris, C B Drachenberg, A B Fogo, P Furness, L W Gaber, I W Gibson, D Glotz, J C Goldberg, J Grande, P F Halloran, H E Hansen, B Hartley, P J Hayry, C M Hill, E O Hoffman, L G Hunsicker, A S Lindblad, Y Yamaguchi and et al.: The Banff 97 working classification of renal allograft pathology. Kidney Int, 55(2), 713-23 (1999) DOI: 10.1046/j.1523-1755.1999.00299.x
80. Ojo, A O, P J Held, F K Port, R A Wolfe, A B Leichtman, E W Young, J Arndorfer, L Christensen and R M Merion: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med, 349(10), 931-40 (2003) DOI: 10.1056/NEJMoa021744
81. Schwarz, A, H Haller, R Schmitt, M Schiffer, C Koenecke, C Strassburg, F Lehner, J Gottlieb, C Bara, J U Becker and V Broecker: Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues. Am J Transplant, 10(9), 2017-25 (2010) DOI: 10.1111/j.1600-6143.2010.03224.x
82. Gallagher, M, M Jardine, V Perkovic, A Cass, S McDonald, J Petrie and J Eris: Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation, 87(12), 1877-83 (2009) DOI: 10.1097/TP.0b013e3181a76823
83. Sollinger, H W: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation, 60(3), 225-32 (1995) DOI: 10.1097/00007890-199508000-00003
84. Naesens, M, E Lerut, B V Damme, Y Vanrenterghem and D R Kuypers: Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant, 7(9), 2114-23 (2007) DOI: 10.1111/j.1600-6143.2007.01892.x
85. Murphy, G J, J R Waller, R S Sandford, P N Furness and M L Nicholson: Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. Br J Surg, 90(6), 680-6 (2003) DOI: 10.1002/bjs.4134
86. Irish, W, B Sherrill, D C Brennan, J Lowell and M Schnitzler: Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Transplantation, 76(12), 1686-90 (2003) DOI: 10.1097/01.TP.0000090865.20886.B7
87. Meier-Kriesche, H U, J D Schold, T R Srinivas, R J Howard, S Fujita and B Kaplan: Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant, 5(9), 2273-80 (2005) DOI: 10.1111/j.1600-6143.2005.01019.x
88. Kahan, B D: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet, 356(9225), 194-202 (2000) DOI: 10.1016/S0140-6736(00)02480-6
89. Halloran, P F: Sirolimus and cyclosporin for renal transplantation. Lancet, 356(9225), 179-80 (2000) DOI: 10.1016/S0140-6736(00)02473-9
90. Ciancio, G, G W Burke, J J Gaynor, P Ruiz, D Roth, W Kupin, A Rosen and J Miller: A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation, 81(6), 845-52 (2006) DOI: 10.1097/01.tp.0000203894.53714.27
91. Lewis, E J, L G Hunsicker, R P Bain and R D Rohde: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med, 329(20), 1456-62 (1993) DOI: 10.1056/NEJM199311113292004
92. Jafar, T H, C H Schmid, M Landa, I Giatras, R Toto, G Remuzzi, G Maschio, B M Brenner, A Kamper, P Zucchelli, G Becker, A Himmelmann, K Bannister, P Landais, S Shahinfar, P E de Jong, D de Zeeuw, J Lau and A S Levey: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med, 135(2), 73-87 (2001) DOI: 10.7326/0003-4819-135-2-200107170-00007
93. Hiremath, S, D Fergusson, S Doucette, A V Mulay and G A Knoll: Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant, 7(10), 2350-60 (2007) DOI: 10.1111/j.1600-6143.2007.01928.x
94. Akalin, E, S Dikman, B Murphy, J S Bromberg and W W Hancock: Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant, 3(9), 1116-20 (2003) DOI: 10.1034/j.1600-6143.2003.00151.x
95. Ivanyi, B: Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection. Nephrol Dial Transplant, 18(4), 655-60 (2003) DOI: 10.1093/ndt/gfg139
96. Gloor, J M, S Sethi, M D Stegall, W D Park, S B Moore, S De Goey, M D Griffin, T S Larson and F G Cosio: Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant, 7(9), 2124-32 (2007) DOI: 10.1111/j.1600-6143.2007.01895.x
97. Akalin, E, R Dinavahi, S Dikman, G de Boccardo, R Friedlander, B Schroppel, V Sehgal, J S Bromberg, P Heeger and B Murphy: Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol, 2(6), 1261-7 (2007) DOI: 10.2215/CJN.02420607
98. Joosten, S A, Y W Sijpkens, V van Ham, L A Trouw, J van der Vlag, B van den Heuvel, C van Kooten and L C Paul: Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant, 5(2), 383-93 (2005) DOI: 10.1111/j.1600-6143.2005.00690.x
99. Dinavahi, R, A George, A Tretin, E Akalin, S Ames, J S Bromberg, G Deboccardo, N Dipaola, S M Lerner, A Mehrotra, B T Murphy, T Nadasdy, E Paz-Artal, D R Salomon, B Schroppel, V Sehgal, R Sachidanandam and P S Heeger: Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol, 22(6), 1168-78 (2011) DOI: 10.1681/ASN.2010111183
100. Cosio, F G, J M Gloor, S Sethi and M D Stegall: Transplant glomerulopathy. Am J Transplant, 8(3), 492-6 (2008) DOI: 10.1111/j.1600-6143.2007.02104.x
101. Kim, M G, Y J Kim, H Y Kwon, H C Park, T Y Koo, J C Jeong, H J Jeon, M Han, C Ahn and J Yang: Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Nephrology (Carlton), 18(12), 820-6 (2013) DOI: 10.1111/nep.12157